GLP-1 agonists such as exenatide, liraglutide, lixisenatide, and taspoglutide have emerged as crucial treatments for non-insulin-dependent diabetes mellitus due to their positive effects like sulfonylureas (SUR) [45]. Here, GCG is linked to type 1 diabetes mellitus.